IQGAP1 and cancer: Utilizing a well-validated mouse model for HNSCC that makes use of a synthetic oral carcinogen (4-nitroquinoline 1-oxide, 4NQO), we discovered that Iqgap1−/− mice developed significantly lower incidences of cancer, reduced severity (i.e., grade) of disease, and fewer cancer foci per mouse than Iqgap1+/+ mice [51].